ITabMed

About ITabMed

ITabMed is a clinical-stage biotechnology company headquartered in Shanghai, China, that specializes in developing immunotherapy treatments for cancer and autoimmune diseases. Founded in 2020 by Dr. Xiaoqiang Yan, the company was established as a spin-off from Generon BioMed Ltd. to continue the development of products from the proprietary iTAb™ platform. Dr. Yan, who serves as CEO, brings over 30 years of experience in biopharmaceutical drug discovery and development, particularly in oncology and immunology, and is a serial entrepreneur with numerous patents and publications.

The company's core technology is the iTAb™ (immunotherapy antibody) platform, which has been refined over more than a decade to create bi- and tri-specific T-cell engagers. This platform develops antibody molecules that bind to cancer cells and simultaneously activate the patient's T-cells to attack and destroy the tumor. A key feature of the iTAb™ products is the absence of an Fc fragment, which helps avoid certain off-target toxicities while maintaining potent T-cell engagement. The products developed through this platform, such as A-319 and A-337 which are in Phase I clinical trials, are designed to have improved safety profiles and address manufacturing challenges common in the field. The platform can also create molecules targeting multiple antigens, reducing the likelihood of cancer cells escaping treatment.

ITabMed operates by discovering and advancing novel antibody candidates through pre-clinical and clinical development, following guidelines from the NMPA, FDA, and EMA. The business model is focused on research and development, funded by venture capital. In December 2021, ITabMed closed a $20 million Series A financing round co-led by 3E Bioventures Capital and Yonjin Capital, with participation from Binhai Venture Capital. The company's therapies are also being explored for autoimmune conditions like systemic lupus erythematosus and multiple sclerosis.